Alpha IVF Group Bhd.
MMYX:ALPHA0.28
MYR
+0.00
(-1.75%)
ISIN
MYQ0303OO006
Return %
Stock
S&P 500
1Y
-15.15
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Soon Soo Lee
- Full Time Employees
- 233
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Petaling Jaya Malaysia
- IPO Date
- Mar 22, 2024
- Website
- alphaivfgroup.com
- Similar Companies
- Business
- Alpha IVF Group Berhad is a Malaysia-based fertility care specialist providing assisted reproductive technology (ART) and comprehensive women’s healthcare services. Founded in 2011 and headquartered in Petaling Jaya, Selangor, Malaysia, the company operates full-fledged fertility centres, satellite clinics, and specialist consultation facilities catering to domestic and international patients across Southeast Asia and Greater China. Alpha IVF Group Berhad delivers a wide spectrum of clinical fertility solutions and medical services, including assisted reproductive treatments such as in-vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), gamete intrafallopian transfer (GIFT), and ovulation induction; advanced genetic screening and diagnostics comprising pre-implantation genetic testing for aneuploidies (PGT-A), monogenic diseases (PGT-M), and structural rearrangements (PGT-SR), next-generation sequencing (NGS), and artificial intelligence-assisted embryo selection; cryopreservation and storage solutions for oocytes, sperm, and embryos; specialized fertility techniques encompassing microfluidic sperm sorting, endometrial receptivity analysis, and saviour sibling programmes; and general women’s healthcare services covering gynaecological consultations, 4D ultrasound imaging, laparoscopic surgery, and hysteroscopy. The company operates medical facilities across Malaysia, Singapore, and the Philippines, supported by satellite clinics in Indonesia and sales representative offices in Shanghai and Guangzhou, China. Recent corporate developments include the company’s initial public offering on the ACE Market of Bursa Malaysia in March 2024 to fund regional capacity expansion and laboratory technology investments; the operational launch of new fertility facilities in Manila, Philippines, and Kota Kinabalu, Malaysia; the expansion of its clinical footprint into Indonesia through new clinical setups in Jakarta and Medan as well as facility development in the Sanur Special Economic Zone in Bali; and the consolidation of regional operating assets via an increased equity stake in its Singapore subsidiary, Alpha International Women’s Specialists (S) Pte. Ltd.